Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Hematology

The Genetics of Iron Loading: Why Your "Internal Factory" is Broken

At a Glance

Inherited microcytic anemia can cause liver iron overload when genetic changes disrupt iron transport or hemoglobin production. Poor red blood cell production lowers the body's iron-control signal, while transfusions may add more iron.

To understand why your body is both functionally restricted from using iron and overloaded by it, we must look at the microscopic “factory” inside your developing red blood cells. In these rare conditions, a single genetic error acts like an impaired gear in a complex machine. While the result—microcytic anemia—looks similar on a standard blood test, the biological cause depends entirely on which gene is affected.

The Role of Three Key Areas

Many classical cases of inherited iron-loading microcytic anemia stem from a defect in one of three areas: getting iron into the cell, getting the raw materials into the cell’s “powerhouse” (the mitochondria), or building the iron into hemoglobin [1]. (Note that acquired causes, such as alcohol exposure, copper deficiency, zinc excess, or medication effects, can also produce sideroblastic findings, and other rare genes exist).

1. DMT1 Deficiency (The Transport Clog)

The SLC11A2 gene provides instructions for a protein called DMT1. Think of DMT1 as a specialized gatekeeper that moves iron into the main body of the cell [2].

  • The Problem: In this deficiency, the gate is impaired. Even though iron is knocking at the door, it cannot get inside the developing red blood cell to make hemoglobin [3].
  • The Result: Your red blood cells are small and iron-restricted. Paradoxically, your body tries to compensate by keeping other iron “gates” wide open, leading to secondary hepcidin suppression and iron buildup in the liver [4].

2. Congenital Sideroblastic Anemias (The Assembly Error)

Sideroblastic anemias occur when the cell has iron, but cannot use it to build heme (the part of hemoglobin that holds oxygen) [5]. This causes iron to pile up inside the mitochondria, forming a visible ring under a microscope called a ring sideroblast [6].

  • ALAS2 (The Enzyme Defect): The ALAS2 gene creates an enzyme that starts the heme-making process [7]. This enzyme requires pyridoxine (Vitamin B6) to function. Some people with this mutation have an enzyme that is “sluggish” but can be jump-started with a supervised trial of high-dose Vitamin B6, leading to improved blood counts [8][9].
  • SLC25A38 (The Raw Material Defect): This gene acts like a conveyor belt, bringing an amino acid called glycine into the mitochondria so the ALAS2 enzyme can use it [10]. If this conveyor belt is broken, the enzyme cannot work, no matter how much B6 is present [11]. This form is typically more severe and often requires regular blood transfusions starting in infancy [12][13].

3. Thalassemia (The Construction Defect)

Unlike the conditions above, thalassemia is not a problem with iron or heme, but with the “scaffolding” of the red blood cell: the globin chains [14]. When these chains are missing or deformed, the cell cannot mature properly [15].

Why the Liver Gets Overloaded

Many of these defects lead to ineffective erythropoiesis—a state where your bone marrow is working overtime to produce red blood cells, but they are “low quality” and die before they can ever enter your bloodstream [16].

This impaired production sends an emergency signal to the rest of the body. Your marrow produces a hormone called erythroferrone [17]. This hormone travels to the liver and suppresses hepcidin, your body’s natural “brake” for iron absorption [18][19]. Without hepcidin, your intestines absorb increased iron from your diet, and your body’s internal iron stores enter the blood [20]. This excess iron is distributed into your organs, particularly the liver and heart [21][22]. Additionally, patients who require blood transfusions receive large amounts of external iron directly into their bloodstream.

Condition Gene Example Primary Mechanism Typical Severity (varies by variant, age, transfusions)
DMT1 Deficiency SLC11A2 Iron cannot enter the cell Moderate to Severe
XLSA ALAS2 Heme assembly is broken Mild to Moderate; some B6-responsive
ARCSA SLC25A38 Glycine cannot enter mitochondria Severe; often transfusion-dependent
Thalassemia HBA or HBB Globin scaffolding is broken Variable (Minor to Major)

Understanding your specific genetic subtype is vital because it explains why your body behaves this way and helps your doctors determine if simpler treatments might help, or if more intensive management is required [23]. Note that a negative genetic panel or a “variant of uncertain significance” does not exclude a genetic diagnosis, as testing may miss certain mechanisms.

Common questions in this guide

How can someone have small red blood cells and too much iron?
An inherited problem may keep developing red blood cells from using or moving iron correctly even as the body continues to absorb and store it. Ineffective blood-cell production can lower hepcidin, a hormone that normally limits iron absorption, and transfusions can add still more iron.
Which genes can cause inherited microcytic anemia with iron overload?
Examples include SLC11A2, which makes the DMT1 iron transporter; ALAS2, which starts production of heme, the iron-containing part of hemoglobin; and SLC25A38, which helps move glycine into mitochondria. HBA and HBB changes can cause thalassemia by disrupting globin chains. The specific gene and variant can affect severity and treatment choices.
Could vitamin B6 help if I have an ALAS2 mutation?
Some ALAS2 variants produce an enzyme that responds to pyridoxine, or vitamin B6, and a supervised high-dose trial may improve blood counts. It does not work for every ALAS2 mutation, and high-dose vitamin B6 should only be used under medical supervision.
What does a ring sideroblast mean?
A ring sideroblast is an immature red blood cell with iron collected around its mitochondria, the cell structures that help make energy. It suggests that iron is present but is not being incorporated into heme properly, as can occur in congenital sideroblastic anemia.
Why can these disorders cause iron to build up in the liver?
When the bone marrow makes many red blood cells that fail before reaching the bloodstream, it releases signals that reduce hepcidin, the body's iron-absorption brake. The intestines then absorb more dietary iron, and the liver stores the excess; transfusions can add another source of iron.
Does a negative genetic panel rule out an inherited cause of my anemia?
No. Genetic panels may miss certain disease-causing changes, and a variant of uncertain significance does not by itself confirm or exclude the diagnosis. A hematologist or medical geneticist can interpret the results alongside blood counts, iron studies, family history, and other findings.
When might a bone marrow transplant be considered for SLC25A38-related anemia?
SLC25A38-related congenital sideroblastic anemia can be severe and may require regular transfusions from infancy. Because a bone marrow transplant is an intensive treatment, its timing and suitability depend on disease severity, transfusion needs, overall health, and specialist evaluation.

Get notified when new evidence is published on Microcytic anemia with liver iron overload.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (23)
  1. 1

    Inherited microcytic anemias.

    Cappellini MD, Russo R, Andolfo I, Iolascon A

    Hematology. American Society of Hematology. Education Program 2020; (2020(1)):465-470 doi:10.1182/hematology.2020000158.

    PMID: 33275715
  2. 2

    Discovery and characterization of a novel non-competitive inhibitor of the divalent metal transporter DMT1/SLC11A2.

    Montalbetti N, Simonin A, Simonin C, et al.

    Biochemical pharmacology 2015; (96(3)):216-24.

    PMID: 26047847
  3. 3

    New Cases of Hypochromic Microcytic Anemia Due to Mutations in the SLC11A2 Gene and Functional Characterization of the G75R Mutation.

    Romero-Cortadellas L, Hernández G, Ferrer-Cortès X, et al.

    International journal of molecular sciences 2022; (23(8)) doi:10.3390/ijms23084406.

    PMID: 35457224
  4. 4

    Inherited iron overload disorders.

    Piperno A, Pelucchi S, Mariani R

    Translational gastroenterology and hepatology 2020; (5()):25 doi:10.21037/tgh.2019.11.15.

    PMID: 32258529
  5. 5

    The role of genetic testing in accurate diagnosis of X-linked sideroblastic anemia: novel ALAS2 mutations and the impact of X-chromosome inactivation.

    Jové-Solavera D, Rámila M, Ferrer-Cortés X, et al.

    Scientific reports 2025; (15(1)):11843 doi:10.1038/s41598-025-95590-x.

    PMID: 40195342
  6. 6

    Establishment of a cell model of X-linked sideroblastic anemia using genome editing.

    Kaneko K, Kubota Y, Nomura K, et al.

    Experimental hematology 2018; (65()):57-68.e2 doi:10.1016/j.exphem.2018.06.002.

    PMID: 29908199
  7. 7

    Regulation and tissue-specific expression of δ-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias.

    Peoc'h K, Nicolas G, Schmitt C, et al.

    Molecular genetics and metabolism 2019; (128(3)):190-197 doi:10.1016/j.ymgme.2019.01.015.

    PMID: 30737140
  8. 8

    A hemizygous p.R204Q mutation in the ALAS2 gene underlies X-linked sideroblastic anemia in an adult Chinese Han man.

    Huang J, Ge M, Shao Y, et al.

    BMC medical genomics 2021; (14(1)):107 doi:10.1186/s12920-021-00950-x.

    PMID: 33858445
  9. 9

    Elucidating the Role of Human ALAS2 C-terminal Mutations Resulting in Loss of Function and Disease.

    Taylor JL, Ayres-Galhardo PH, Brown BL

    Biochemistry 2024; (63(13)):1636-1646 doi:10.1021/acs.biochem.4c00066.

    PMID: 38888931
  10. 10

    Characterization of Human and Yeast Mitochondrial Glycine Carriers with Implications for Heme Biosynthesis and Anemia.

    Lunetti P, Damiano F, De Benedetto G, et al.

    The Journal of biological chemistry 2016; (291(38)):19746-59 doi:10.1074/jbc.M116.736876.

    PMID: 27476175
  11. 11

    Glycine and Folate Ameliorate Models of Congenital Sideroblastic Anemia.

    Fernández-Murray JP, Prykhozhij SV, Dufay JN, et al.

    PLoS genetics 2016; (12(1)):e1005783 doi:10.1371/journal.pgen.1005783.

    PMID: 26821380
  12. 12

    Clinical characterization and hematopoietic stem cell transplant outcomes for congenital sideroblastic anemia caused by a novel pathogenic variant in SLC25A38.

    Uminski K, Houston DS, Hartley JN, et al.

    Pediatric blood & cancer 2020; (67(10)):e28623 doi:10.1002/pbc.28623.

    PMID: 32790119
  13. 13

    Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.

    Cazzola M, Malcovati L

    Hematology. American Society of Hematology. Education Program 2015; (2015()):19-25 doi:10.1182/asheducation-2015.1.19.

    PMID: 26637696
  14. 14

    Alpha- and Beta-thalassemia: Rapid Evidence Review.

    Baird DC, Batten SH, Sparks SK

    American family physician 2022; (105(3)):272-280.

    PMID: 35289581
  15. 15

    RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.

    Schmidt PJ, Liu K, Visner G, et al.

    American journal of hematology 2018; (93(6)):745-750 doi:10.1002/ajh.25079.

    PMID: 29498084
  16. 16

    Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.

    Srole DN, Ganz T

    Journal of cellular physiology 2021; (236(7)):4888-4901 doi:10.1002/jcp.30247.

    PMID: 33372284
  17. 17

    Erythroferrone inhibits the induction of hepcidin by BMP6.

    Arezes J, Foy N, McHugh K, et al.

    Blood 2018; (132(14)):1473-1477 doi:10.1182/blood-2018-06-857995.

    PMID: 30097509
  18. 18

    Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

    Kautz L, Jung G, Du X, et al.

    Blood 2015; (126(17)):2031-7 doi:10.1182/blood-2015-07-658419.

    PMID: 26276665
  19. 19

    Iron metabolism and iron disorders revisited in the hepcidin era.

    Camaschella C, Nai A, Silvestri L

    Haematologica 2020; (105(2)):260-272 doi:10.3324/haematol.2019.232124.

    PMID: 31949017
  20. 20

    Iron Mining for Erythropoiesis.

    Correnti M, Gammella E, Cairo G, Recalcati S

    International journal of molecular sciences 2022; (23(10)) doi:10.3390/ijms23105341.

    PMID: 35628152
  21. 21

    Non-transferrin-bound iron transporters.

    Knutson MD

    Free radical biology & medicine 2019; (133()):101-111 doi:10.1016/j.freeradbiomed.2018.10.413.

    PMID: 30316781
  22. 22

    Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

    de Swart L, Hendriks JC, van der Vorm LN, et al.

    Haematologica 2016; (101(1)):38-45 doi:10.3324/haematol.2015.133983.

    PMID: 26385212
  23. 23

    Novel frameshift variant (c.409dupG) in SLC25A38 is a common cause of congenital sideroblastic anaemia in the Indian subcontinent.

    Ravindra N, Athiyarath R, S E, et al.

    Journal of clinical pathology 2021; (74(3)):157-162 doi:10.1136/jclinpath-2020-206647.

    PMID: 32605921

This page explains genetic causes of microcytic anemia and iron overload for informational purposes only and does not constitute medical advice. A hematologist and genetics team should interpret your test results and discuss treatments such as vitamin B6 or transplantation.

Guide contents Microcytic anemia with liver iron overload
Research & Literature
01 The Iron Paradox 03 Getting the Right Diagnosis